(1) The genome is ~9.6 kilobases (kb) long with a single open reading frame and flanking 5' and 3' untranslated regions (UTRs) with specific RNA structure for viral RNA replication and translation (Fig. 1) . HCV has been classified into seven genotypes and several subtypes based on the genomic sequence variations.
H epatitis C virus (HCV) is hepatotropic, and belongs to the Flaviviridae family. The HCV genome consisting of a positive strand RNA was identified almost 30 years ago.
(1) The genome is ~9.6 kilobases (kb) long with a single open reading frame and flanking 5' and 3' untranslated regions (UTRs) with specific RNA structure for viral RNA replication and translation (Fig. 1) . HCV has been classified into seven genotypes and several subtypes based on the genomic sequence variations.
(2) HCV genotypes 1, 2, and 3 are the most prevalent relative to the other genotypes. The HCV genome encodes a polyprotein of ~3,000 amino acids that is cleaved by cellular and viral proteases. Three structural proteins (Core, E1, and E2) are cleaved by cellular proteases, and the seven nonstructural proteins (p7, nonstructural protein [NS] 2, NS3, NS4A, NS4B, NS5A and NS5B) are cleaved by virus encoded proteases. (3, 4) The HCV Core protein encapsidates the positive strand viral genome. In addition, several investigators have shown multiple functional properties, including the oncogenic potential of HCV Core protein. (5) HCV envelope glycoproteins, E1 and E2, bind to the host proteins (designated as binding factors, coreceptors, or receptors) and promote virus entry into cells. P7 is a viroporin which is involved in HCV assembly. HCV nonstructural proteins, NS2 to NS5B, play a role in virus replication and assembly. Several host factors are involved in the virus replication and assembly processes, which are eloquently discussed in other reviews. (3, 4, 6) HCV exploits autophagy machinery for virus growth. (7) (8) (9) Light chain 3 (LC3) lipidation is a key event in autophagosome formation and is induced upon HCV infection. Autophagosomes also serve as a platform for HCV RNA synthesis, (9) suggesting that the influence of autophagy on HCV replication is complex. Mature HCV particles are released from hepatocytes primarily through secretory pathways. (4) Interestingly, exosomes-a component of microvesicles-carry viral genome and promote viral spread to naïve hepatocytes. (10) (11) (12) Generation of infectious HCV is very much restricted in human hepatocytes, aRtICle INFoRMatIoN:
FIg. 1. HCV genome and proteins. The single-strand HCV RNA of the ~9.6-kb genome is shown. The 5ʹ UTR contains an internal ribosome entry site (IRES). The 3ʹ UTR contains a variable poly(U/UC) tract, followed by a conserved ~100 nucleotides that constitute the 3ʹ X-tail sequence. The IRES-mediated translation of the open reading frame leads to the generation of a single polyprotein, which is processed to 10 viral proteins by cellular proteases (shown by purple and pink arrows) and viral protease (shown by blue or green arrows). Three structural proteins (Core, E1, and E2) are processed from the amino terminus of the polyprotein. The nonstructural proteins p7 (viroporin-an ion channel) and NS2 (a cis-acting protease) are important for virus morphogenesis. Other nonstructural proteins: NS3 (protease and helicase), NS4A (protease cofactor of NS3), NS4B (integral membrane protein), NS5A (phosphoprotein), and NS5B (RNA-dependent RNA polymerase) are required for RNA replication. DAAs targeting HCV proteins are shown at the bottom.
even though difficult to grow in culture. HCV genotype 2a growth in cell culture was first developed by Wakita et al., (13) and limited HCV genotype 1a growth was also reported. (14, 15) Despite a number of obstacles, major global research effort from the scientific community has illuminated many aspects of the HCV life cycle, facilitating the development of DAA with a sustained virological response. (16, 17) These antivirals consist of NS3/4A protease inhibitors (which inhibit protease activity), NS5A phosphoprotein inhibitors and non-nucleoside polymerase inhibitors (which inhibit biogenesis of membranous web and assembly), and nucleoside and nucleotide NS5B polymerase inhibitors (which block viral RNA synthesis).
Innate Immune Response to HCV Infection

INteRFeRoN ReSpoNSe
To understand the mechanism by which HCV antagonizes interferon (IFN) signaling, several viral proteins were studied. HCV E2 and NS5A proteins interact with interferon-induced serine/threonine protein kinase and disrupt eukaryotic initiation factor 2 alpha phosphorylation. (18) HCV-infected hepatocytes display up-regulation of total signal transducer and activator of transcription (STAT) 1 without detectable phosphorylated STAT1, and modest activation of the IFN-stimulated response element (ISRE) promoter. (19) HCV Core protein induces suppressor of cytokine signaling 3 (SOCS3) and SOCS1 expression, which blocks STAT1 function. In the early phase of infection, HCV NS3/4A cleaves host protein mitochondrial antiviral signaling protein (MAVS) and fails to transduce retinoic acid inducible gene-I (RIG-I)/ melanoma differentiation-associated gene 5 (MDA5) signal for IFN regulatory factor (IRF) 3/IFN-β activation. (18) Another study showed that interference of mitochondrial fission significantly increases ISRE activities, (20) suggesting that HCV evolved strategies, independent of NS3/4A, in modulating innate immune responses.
The level of IFN-α production in HCV-infected patients varies. IRF-7, one of the IFN-stimulated genes (ISGs), plays a major role in IFN-α production. IRF-7 undergoes phosphorylation when activated and translocates into the nucleus. IRF-7 amplifies the type I IFN response by inducing expression of IFN-α, which also acts in both auto-and paracrine manners through the IFN-α/β receptor. Interestingly, IRF-7 remains localized in the cytoplasm of HCV-infected hepatocytes. (19) The initial burst of IFN expression following HCV infection may occur from uncoating of the virus genome and RNA replication. However, this activation may not be sufficient to trigger high enough antiviral responses for HCV clearance, given that virus infection fails to translocate IRF-7 and inhibits IFN-α synthesis. HCV infection also inhibits IFN-stimulated gene factor 3 (ISGF3) complex formation by targeting protein phosphatase 2A (PP2A) in the IFN signaling pathway. (21) MicroRNAs (miRNAs) are small noncoding RNAs that play an important role in several signal transduction pathways, including IFN signaling. miR130a is elevated in HCV-infected liver tissues and cells and interferes with IFN signaling by targeting IFN-induced transmembrane protein 1 (IFITM1). (22) Furthermore, HCV infection induces miR-373 in hepatocytes, which directly targets Janus kinase 1 ( JAK1) and IRF9, and negatively regulates the type I IFN signaling pathway. (23) Pathogen recognition receptors (PRRs) recognize viral pathogen-associated molecular patterns (PAMPs) during acute virus infection. (18, 24, 25) The RIG-I-like receptors are cytoplasmic RNA helicases that function as PRRs for the recognition of HCV RNA following virus infection. The length of the poly-uridine core (U-core) within the poly-U/UC tract and the 5'-triphosphate of HCV RNA are essential components for RIG-I recognition, and activates transcription factors and type I and type III IFN production, triggering innate antiviral immunity to HCV infection. (24) Thus, HCV interferes with the IFN pathway at many different levels for establishment of persistent infection (Fig. 2) . aUtopHagy HCV-induced autophagy has been demonstrated by several investigators. The question is whether HCV-induced autophagy is a friend or foe for the virus for establishment of chronic infection and IFN signaling. Hepatocytes subjected to genetic interference of Beclin-1 or ATG7 (autophagy related 7; a key molecule of autophagy signaling), when infected with HCV, activate the type I IFN signaling pathway, resulting in an inhibition of viral growth. (26) A different study demonstrated that suppression of autophagy by depletion of ATG5 or chloroquine treatment of HCV-infected cells enhance the IFN signaling pathway. HCV-induced autophagy also depletes TNF receptor-associated factor 6, which, in turn, suppresses nuclear factor kappa B (NF-κB) activation, induces proinflammatory cytokines (interleukin [IL]-6 and tumor necrosis factor alpha [TNF-α]), and enhances HCV replication. (9) IFN-λ1 treatment inhibits autophagic activity in Huh7 cells by down-regulating the expression of ATG5 and aminobutyric acid receptor-associated protein through miR-181a and miR-214 and contributes to anti-HCV activity. (27) Together, these results support the notion that HCV-induced autophagy favors virus growth by negatively regulating the IFN response in the host cell.
INFlaMMaSoMe aCtIVatIoN
Inflammasome is a multiprotein complex that regulates the innate immune system. Inflammasome responds to PAMPs after exposure to microbial infection. (28) IL-1β and IL-18 are the important players in inflammasome-dependent processes. A high level of IL-18 is detected in the acute phase of HCV infection. HCV induces secretion of IL-1β/IL-18 in the THP-1 cell line (a macrophage cell-culture model), human peripheral blood mononuclear cell-derived macrophages, and primary human Kupffer cells (KCs; liver resident macrophages). (29) (30) (31) Induction of these proinflammatory cytokines occurs by the NF-κB signaling pathway, suggesting that HCV initiates the inflammasome signal 1 pathway in macrophages. In fact, HCV p7 RNA alone can induce IL-1β from macrophages, which can be inhibited by KCl or amantadine, an ion channel blocker. (29) In agreement, HCV-incubated macrophages reduce IL-1β maturation upon pretreatment with a potassium channel inhibitor. (30) HCV poly(U/UC) RNA transfected into macrophages also induces IL-1β secretion. (24) The biological outcome of HCV-induced inflammasome activation in macrophages is still under investigation. Induction of IL-1β/IL-18 may have positive or negative influence in hepatic inflammation and disease outcome. Interestingly, HCV-induced IL-1β from macrophages does not induce inflammation or activation in human hepatic stellate cells (HSCs). (32) However, HCV does establish chronic infection. Therefore, it is possible that production of IL-1β/ IL-18 may not be enough for virus clearance, thus leading to chronicity. Together, these observations implicate that HCV utilizes multiple strategies for triggering inflammasome activation in macrophages.
NatURal KIlleR Cell RegUlatIoN
Hepatic resident natural killer (NK) cells expand and/or recruit NK cells from the blood during infection. NK cells induce early innate immune responses to infection from pathogens. These cells either directly target infected hepatocytes or act indirectly by influencing other immune cells, such as DCs or T cells for virus clearance. A human study suggests sustained NK cell activation for protection against HCV infection, (33) although the role of NK cells in HCV infection, especially in the context of viral control, remains to be understood. A rapid and strong NK cell response at an early stage of infection may result in T-cell responses for virus clearance. However, chronic HCV infection associates with dysfunctional NK cell phenotypes. NK cells secrete IFN-γ as a major cytokine, and the lack of IFN-γ production by NK cells impairs HCV clearance. The acute phase of HCV infection activates NK cells, whereas chronic infection impairs NK cell frequency, phenotype, and function. A polarized NK cell phenotype is induced from chronic HCV infection and IFN-α production. This phenotype may contribute to liver injury by TNF-related apoptosis-inducing ligand expression and cytotoxicity. NK cells from HCV-infected patients express inhibitory receptors and cytokines, such as transforming growth factor beta (TGF-β) and IL-10, in attenuating adaptive immune responses. (33, 34) NK cells exposed to HCV-infected hepatocytes fail to increase complement synthesis for inhibition of major histocompatibility complex (MHC) class I-related chains A and B expression as ligands for cell killing. Natural killer group 2, member D expression is lower in circulating NK cells from chronically HCV-infected patients. Thus, impairment of NK cell function in chronic HCV-infected humans may significantly impact the innate immune response.
CoMpleMeNt RegUlatIoN
The complement system is a group of proteins that works for the innate and adaptive immune responses. Complements play a role in inflammation by promoting dendritic cell (DC)-mediated NK cell activation. + T cells increases and maintains during HCV infection, whereas this does not occur in individuals resolving HCV infection. C3 complement component is an important mediator of antibody and T-cell immune responses. C3 facilitates antigen uptake/presentation and immune cell priming. During a systemic viral infection, C3 activity is required for optimal CD8 + T-cell expansion. Serum C3 level is depleted in HCV-infected patients with cirrhosis. HCV E2 envelope glycoprotein suppresses C3 expression and impairs macrophage and DC maturation for antigen presentation and CD4 + T cell stimulation. (37, 38) HCV induces CD55 as a negative regulator of complement activation and suppresses C3, C4, and C9 complement components of the membrane attack complex. Up-regulation of CD55 expression on the cell surface or secretion by HCV core protein inhibits complement-dependent cytolysis. (39) Antibodies against cancer cell-surface proteins enhance complement-dependent cytolysis or antibody-dependent, cell-mediated cytotoxicity. HCV-induced cell-surface CD55 expression, and secretory CD55 expression in the tumor microenvironment limit complement-mediated damage of HCV-infected cells, favoring cell survival and growth promotion. Together, this information highlights the cooperative approach of individual HCV proteins in the control of host NK cells, and complement components or complement-associated CD55 protein functions for protection of tumor cell killing. (41, 49, 50) Combined PD-1 and CTLA-4 blockade helps to rescue their in vitro function. (51) Genetic factors, including killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 gene, combined with its ligand, the human leukocyte antigen (HLA)-C1, allele determine the fate of acute HCV infection. (52) HLA-B27, HLA-B57, and HLA-A3 allotypes associate with spontaneous HCV clearance. (53) Together, these results implicated the important role of HCV-specific cellular immune responses in protection.
Regulation of the Adaptive
HCV-Associated Metabolic Disorders
Chronic HCV infection is associated with increased rates of insulin resistance (IR), diabetes, and steatosis. (54) (55) (56) Liver steatosis is most common among patients infected with HCV genotype 3, possibly attributed to a direct effect of viral proteins, and partially related to metabolic disorders. HCV-mediated IR involves multiple processes, including up-regulation of inflammatory cytokines, phosphorylation of insulin receptor substrate 1, up-regulation of gluconeogenic genes like glucose 6-phosphate and phosphoenolpyruvate carboxykinase 2, and accumulation of lipid droplets. (57, 58) Several mechanisms are proposed to account for the development of steatosis and fatty liver during HCV infection, which include expression of sterol regulatory element-binding protein 1 and fatty acid synthase, controlled by the forkhead box (Fox) transcription factor, FoxO1. (58) Furthermore, HCV infection significantly decreases both medium-chain acyl coenzyme A dehydrogenase and short-chain acyl coenzyme A dehydrogenase expression, controlled by FoxA2. HCV infection also increases lipid droplet accumulation and perilipin-2 expression and decreases hormone-sensitive lipase activity. Knockdown of FoxO1 decreases lipogenesis, and overexpression of FoxA2 increases β-oxidation. FoxO1 and FoxA2 might be useful therapeutic targets for HCV-associated metabolic disorders. HCV infection resembles nonalcoholic steatohepatitis from metabolic disorders by the presence of steatosis, serum dyslipidemia, and oxidative stress in the liver. Steatosis often disappears in genotype 3 patients after treatment and recurs when HCV relapses. HCV infection also induces oxidative stress genes. (59) HCV core protein alters mitochondrial function to increase the cellular abundance of reactive oxygen species (ROS) leading to an increase in cellular lipid peroxidation. (60) Chronic oxidative stress leads to mitochondrial and chromosomal DNA damage. HCV-associated metabolic disorders, oxidative stress, and inflammation result in hepatic fibrogenesis and liver disease progression.
HCV-Associated Inflammation and Liver Pathogenesis
HSC aCtIVatIoN
Understanding the in-depth molecular mechanisms for HCV-mediated pathogenesis are challenging because of the absence of an appropriate animal model. Chronic HCV-infected individuals often develop liver fibrosis/cirrhosis. The link among inflammation, fibrosis/cirrhosis, and HCC associated with HCV infection is an emerging area of research. HCV-associated HSC activation occurs by multiple mechanisms (Fig.  3) . HCV-infected hepatocytes secrete macrophage colony-stimulating factor and IL-34, which, in turn, induce platelet-derived growth factor and TGF-β secretion from monocyte-derived macrophages, and activate HSCs from the resting or quiescent state. (61) Macrophages/KCs exposed to HCV secrete several cytokines and chemokines, including TNF-α, IL-1β, and C-C motif chemokine ligand 5 (CCL5). (32) Recognition of HCV proteins (Core, NS3, NS4, and NS5) by Toll-like receptor (TLR) 4 in KCs during chronic infection increases TNF-α secretion. TNF-α enhances inflammasome markers in primary human HSCs, but does not activate fibrosis marker genes. (32) On the other hand, CCL5, secreted from HCVexposed macrophages/KCs, enhances inflammation FIg. 3 . Cross-talk among HCV-infected hepatocytes with other liver cells. HCV released from infected hepatocytes when exposed to KCs secrete proinflammatory cytokines/chemokines, including TNF-α and CCL5. These mediators promote quiescent HSCs to activated HSCs. On the other hand, HCV-infected hepatocytes secrete TGF-β, which potentiates activation of quiescent HSCs. Exosomes carrying miRNAs, such as miR-19a, secreted from HCV-infected hepatocytes also activate quiescent HSCs. and activation of primary human HSCs. Clinically, HCV-infected individuals display up-regulation of CCL5 in sera and liver (62) that correlates with HCV-RNA load and histological activity index, with or without bridging necrosis and portal inflammation. CCL5 recently gained attention as an antifibrotic target and is the subject of a current clinical trial.
HCV infection initiates an epithelial-mesenchymal transition state and tumor-initiating cancer stem-like cells (TISCs) in human hepatocytes. (63) HCV-induced TISCs, when implanted into immunodeficient mice, activate stromal fibroblasts. (63, 64) TGF-β, a multifunctional cytokine, secreted in conditioned medium from HCV-infected human hepatocytes, activates fibrosis-related markers in HSCs, (32) further suggesting its role in fibrosis activation. Exosomes are extracellular vesicles which are considered important mediators of cell-cell communication by delivering the information they carry to neighboring cells. (65, 66) In the liver, exosomes carrying miRNAs may take part in fibrosis by modulating epigenetic regulation of HSCs. (67) Exosome-mediated intercellular transfer of connective tissue growth factor is also implicated in fine-tuning of liver fibrosis. Exosomes carrying miR-19a shuttle from HCV-infected hepatocytes to HSCs and target SOCS3 to induce the STAT3/TGF-β1 axis for fibrogenic activation. (66) 
poteNtIatIoN oF HCC
Immune-mediated inflammation during chronic HCV infection is implicated in triggering HCC, although the mechanism is not well understood. Several HCV proteins exhibit oncogenic potential. HCV Core protein promotes metabolic disorder, immortalizes primary human hepatocytes, and enhances ROS formation and cell growth. (59, 68) Transgenic mice with liver-specific HCV core protein expression display HCC. HCV NS5A protein is involved with a variety of host signal transduction pathways, such as antiapoptosis, ROS production, immune evasion, and cell proliferation. HCV NS5A binds to tumor suppressor p53, translocates into the cytoplasm, and disrupts p53 activity. (5) Furthermore, HCV core and NS5A proteins inhibit TNF-α-mediated apoptosis. Other HCV proteins, such as E2, NS2, NS3, and NS5B, are also involved in cell growth regulation by interacting with host proteins. HCV-associated metabolic disorders, oxidative stress, and inflammation result in fibrogenesis, cirrhosis, and create genomic instability or a pro-oncogenic microenvironment (Fig. 4) . Therefore, long time interaction of HCV proteins with host cellular proteins and involvement in signaling cascades may promote malignant transformation. 
Vaccine Development
HCV exists as multigenotypes, subtypes, and quasispecies. Thus, an effective vaccine for prevention of HCV infection is a challenging task. An ongoing effort is underway for vaccine development against HCV. An earlier phase I vaccine trial with recombinant HCV E1/E2 envelope glycoproteins did not induce a strong immune response in the majority of the healthy volunteers. (69) Only a small number of neutralization-positive sera showed cross-protection with other HCV genotypes. In a different study, E1 therapeutic vaccination using recombinant envelope glycoprotein in chronically infected patients showed improved liver histopathology. (70) However, therapeutic vaccination might be challenging for already established immune modulation by HCV in a chronically infected host. The importance of broadly neutralizing antibody response and breadth of cellular immune responses for protection against HCV are eminent from the already available information in the literature. A human monoclonal antibody to a discontinuous epitope outside the CD81 binding site of the E1/E2 complex displays broad neutralizing activity to diverse HCV genotypes and protects from heterologous challenge infection in a small animal model. (71) The use of broadly neutralizing antibodies inhibiting HCV infection in a human liver chimeric mouse model also suggested therapeutic potential, (72) especially for preventing cell-to-cell spread of infection.
HCV E2 induces immune regulatory cytokine IL-10 and CD163 protein expression and enhances STAT3 and suppresses STAT1 activation in macrophages, suggesting the possibility for macrophage polarization toward the M2 phenotype. (37) Furthermore, E2 suppresses C3 complement expression, suggesting potential for impairment of immune cell priming. E2-associated macrophage polarization depends on the interaction with CD81 for epidermal growth factor receptor activation. HCV E2 also inhibits the function of NK cells, B cells, and T cells by binding with CD81. (73) Using discrete domains within E2, rather than the entire ectodomain or intact E2 in a vaccine preparation, may prove to be more effective in elliciting a stronger protective immune response.
Predominant CD4 + T-cell epitopes in HCV nonstructural proteins are immunogenic in the context of class II molecules. Replication-defective adenoviral constructs, chimpanzee adenoviral vector, and modified vaccinia Ankara vector are in use as vehicles for vaccine development using HCV nonstructural regions in prime-boost regimens of human trial. (74, 75) Sustained and balanced memory and effector T-cell responses were noted using a prime and boost vaccination strategy. A human efficacy study is underway in a large cohort of high-risk individuals. However, challenges remain for distinct T-cell specificity among different HCV genotypes (76) and duration of the protective immune response. Cocktail DNA vaccine elicits strong cellular immune response to the nonstructural proteins in mice, (77) suggesting potential for universal HCV vaccine development. Immunization with E1, selected regions of E2, and NS3-NS4a by appropriate delivery to the immune system may help in the generation of HCV crossgenotype-specific broad neutralizing antibodies and T-cell responses.
Conclusions
HCV research has made extraordinary progress from discovery of its genome to antiviral agents in less than 25 years. Despite major obstacles, including lack of virus growth in cell culture in the early years and absence of a suitable small animal model for infection as the major tools for research, we have learned numerous biological functions of HCV RNA and proteins over the past several years. The majority of the research efforts were rationalized based on the use of molecular biology and immunology techniques. The use of HCV genomic regions for expression in cell culture, experiments from limited available chimpanzees and genetically-modified small animal models, and clinical studies from HCV-infected humans have significantly advanced the HCV field. Obviously, the road to success was challenging. A major achievement of HCV research is the development of IFN-free DAA with an SVR. Current DAA therapy is well tolerated and works on pan-genotypes in eradicating HCV RNA. However, one major hurdle for HCV-infected individuals is early diagnosis for treatment. We do not have a way to know who is infected, because HCV infection is asymptomatic and causes silent liver disease. Screening for HCV in a high prevalence group and efforts to discover a potential biomarker for progressive liver disease would help in early treatment. miRNAs may act as signature molecules for prediction of HCV chronicity, and work is in progress for identifying predictive biomarkers. Furthermore, DAA treatment cost, potential for reinfection, generation of mutant virus, reactivation of other viruses, and end-stage liver disease progression even after virus clearance raise concerns.
Here, we have discussed numerous ways by which HCV manipulates humans as its favorite host for a long-term relationship and liver injury. We have learned that HCV-induced miRNAs play a role in impairment of IFN signaling and induction of autophagy, which protect the virus from initial host cell insult. Exosomes are secreted from healthy, neoplastic, and virus-infected cells and are gaining attention as a cargo for transport of numerous biologicals by intercellular communications. Primary human HSCs, when exposed to exosomes carrying miRNA from HCV-infected hepatocytes, display fibrogenic activation, implicating that exosomes carry sensors. Further study of exosomes carrying stimuli will provide a rich area to enhance our understanding of the role of exosomes in HCV persistence and pathogenesis. Given that multiple mechanisms are operating for impairment of the innate immune system, HCV also triggers proinflammatory cytokine production for liver pathogenesis. It remains a mystery how HCV overcomes all the barriers of innate immunity pathways for establishment of chronic infection. Further progress would require more-precise understanding on virus and cell interactions for targeted therapy to inhibit liver disease progression. A global need for a comprehensive strategy to control HCV infection requires an effective and safe vaccine. The diversity of the viral genome and the lack of an immunocompetent small animal model are the major obstacles for HCV vaccine development, and work is in progress to overcome these challenges. Thus, understanding host and viral factors will provide important information for successful vaccine-mediated protection and therapeutic approaches for HCV-associated liver disease.
